Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis

Zhi-Yuan Zhang a, *, Rolf Daniels b, Hermann J. Schluesener a

a Division of Immunopathology of the Nervous System, Institute of Pathology and Neuropathology, University of Tuebingen, Tuebingen, Germany
b Department of Pharmaceutical Technology, University of Tuebingen, Tuebingen, Germany

Received: February 11, 2013; Accepted: August 5, 2013

Abstract

Alzheimer’s disease (AD) is the most common form of neurodegeneration and the major cause of dementia. This multifactorial disorder is clinically defined by progressive behavioural and cognitive deficits, and neuropathologically characterized by β-amyloid aggregation, hyperphosphorylated tau and neuroinflammation. Oridonin, a diterpenoid isolated from Chinese herb Rabdosia rubescens, has multiple biological properties, especially anti-inflammatory and neuroregulatory activities. Potential therapeutic effects of Oridonin were investigated in an animal model of cerebral amyloidosis for AD, transgenic APP/PS1 mice. Oridonin was suspended in carboxymethylcellulose or loaded with a nanostructured emulsion, and was orally administrated or injected. Before, during and following the experimental treatments, behavioural tests were performed with these transgenic mice and their naive littermates. Following relatively short-term treatments of 10 days, brain tissue of mice were removed for immunohistochemical assays. The results indicate that both oral treatment and injection of Oridonin significantly attenuated β-amyloid deposition, plaque-associated APP expression and microglial activation in brain of transgenic mice. Furthermore, injection of Oridonin-nanoemulsion ameliorated deficits in nesting, an important affiliative behaviour, and in social interaction. Additional in vitro studies indicated that Oridonin effectively attenuated inflammatory reaction of macrophage and microglial cell lines. Our results suggest that Oridonin might be considered a promising therapeutic option for human AD or other neurodegenerative diseases.

Keywords: Alzheimer’s disease ● APP/PS1 transgenic mouse ● oridonin ● nanoemulsion ● cerebral amyloidosis ● neuroinflammation ● non-mnemonic behaviour

Introduction

Alzheimer’s disease (AD) is the most common form of neurodegeneration and the major cause of dementia. Alzheimer’s disease is clinically defined by distinct behavioural and cognitive deficits, and is neuropathologically characterized by typical extracellular deposits of aggregated β-amyloid (Aβ) peptide (amyloid plaques).

β-amyloid peptides are toxic and causative in AD, and contribute to memory loss and neurodegenerative pathology [1]. Besides, other mechanisms, such as neuroinflammation, play important roles in the pathophysiology of this multifactorial disorder [2]. Neuroinflammation is characterized by release of numerous inflammatory mediators and glial activation [3, 4]. Neuroinflammation may contribute independently to neural dysfunction and cell death, establishing a self-perpetuating vicious cycle by which inflammation induces further neurodegeneration [5]. The understanding of neuroinflammation leads to a concept that anti-inflammatory agents may have beneficial effects on neurodegenerative disorders. Indeed, several anti-inflammatorials markedly reduced the risk of suffering from this neurologic condition, delayed its onset, ameliorated the symptomatic severity and improved/slowed cognitive decline of AD patients [5].

Some terpenoids such as ginsenosides, gingkolides and canabino-oids are suggested as potential anti-AD agents, as they exhibit promising in vitro and in vivo biological activities [6]. Further studies also suggested potential therapeutic application of diterpenoids for neurogenerative disorders [7–9]. Oridonin, a natural diterpenoid compound (Fig. 1) [10], isolated from Chinese herb Rabdosia rubescens,
exhibits a variety of biological properties: anti-bacterial, oxygen free-radical scavenging, anti-mutagenic and remarkable anti-neoplastic activities [11, 12]. Recently, anti-neuroinflammatory and neuroregulatory effects have been reported or suggested by several in vitro studies [13–15], which may suggest its potential application against neuroinflammation and neurodegenerative disorders.

In this study, we used a APP/PS1-21 double transgenic mouse model on a C57BL/6J genetic background that co-expresses the KM670/671NL mutated human amyloid precursor protein and the L166P mutated human presenilin 1 (APP/PS1-21 mice). This mouse model exhibits very aggressive AD pathology, accompanied by neuroinflammation and impairment of cognitive function [16, 17]. Our aim here was to study potential therapeutic effect of Oridonin on this APP/PS1 mouse model.

Materials and methods

Animals

Male APP/PS1-21 mice were obtained from Prof. Jucker (Hertie-Institute, Tuebingen, Germany). Heterozygous male APP/PS1-21 mice were bred with wild-type C57BL/6J females (Charles River Germany, Sulzfeld, Germany). Offspring were tail snipped and genotyped using PCR with primers specific for the APP-sequence (Forward: “GAATTCCGACATG- chG”) of 2006.

Materials

Oridonin (>99%) was purchased from Carbosynth Ltd. (Compton, Berkshire, UK). For oral treatment, Oridonin was suspended in 1% carboxymethylcellulose (CMC, Blanose®, Hercules-Aqualon, Dusseldorf, Germany) at a concentration of 2 mg/ml. For injection, Oridonin was loaded with a nanostructured carrier, Lipofundin® (MCT, 10% for infusion, B. Braun AG, Melsungen, Germany), by high pressure at a concentration ratio of 2 mg/ml. A quantity of 30 mg Oridonin was first coarsely dispersed in 60 ml Lipofundin. Subsequently, the dispersion was high-pressure homogenized using an EmulsiFlex C3 (Avestin Inc., Canada). At first five cycles at 750 bar and then five cycles at 1750 bar were run yielding ~50 ml of a 2 mg/ml formulation.

Treatment with Oridonin

Six groups of animals (n = 6, three males and three females) were grouped for two experimental treatments: daily oral administration with Oridonin suspension (20 mg/kg bodyweight) at the age of 5 months and daily i.p. injection with Oridonin-nanoemulsion (20 mg/kg bodyweight) at the age of 3 months. Each experiment lasted 10 days and contained three groups: Oridonin treatment, vehicle control and control without any treatment.

Design and evaluation of nest construction assay

A nest construction assay [18] was modified to determine the deficits in affiliative/social behaviour of these APP/PS1 mice and potential changes following treatment.

Mice were individually housed for at least 24 hrs in clean plastic cages with ~1 cm of wood chip bedding. Two hours prior to the onset of the dark phase, individual cages were supplied with paper towel torn into ~5 × 5 cm squared pieces. The next morning, cages were inspected for nest construction. Paper towel nest construction was scored by a three-point system: 1 = no biting or tears on the paper, 2 = moderate biting and/or tears on the paper but no coherent nest and 3 = the vast majority of paper torn into pieces and grouped into a corner of the cage [18].

Social interaction assay

The social interaction assay was performed according to previous studies [19, 20] with minor modifications. The social interaction assay was video recorded to quantify all distinct behaviours of naive mice, vehicle-treated and Oridonin-treated APP/PS1 mice as ‘resident’ in the presence and absence of an ‘intruder’ mouse. Their movements were then analysed to assess overall activity level and overt neurological differences. Individual mice were placed in a clean plastic housing cage identical with the home cage for 15 min. to establish each as the ‘resident’ mouse. An age-, weight- and gender-matched non-treated naive mouse was introduced as the ‘intruder’ for a second 15 min. period. Both 15 min. sessions were video recorded, all identifiable distinct independent and interactive behavioural events [19, 20], for the resident mouse (15 min alone; 15 min. with intruder) and for the intruder mouse (15 min. with resident), were counted by three independent observers blinded to treatment categories.

Immunohistochemistry and image evaluation/analysis

Oridonin-treated and control mice were killed after 10-days-treatment. They were perfused intracardially with 4°C, 4% paraformaldehyde in PBS. Brains were quickly removed and post-fixed in 4% paraformaldehyde overnight at 4°C. Brains were then cut into two hemispheres, embedded in paraffin, serially sectioned (3 μm) and mounted on silan
covered slides. Hemispheres sections were stained by immunohistochemistry as described previously [21], with following antibodies: β-amyloid (1:100; Abbcam, Cambridge, UK) for Aβ deposition, Iba-1 (1:200; Wako, Neuss, Germany) for activated microglia, GFAP (1:500; Chemicon (Millipore), Billerica, MA, USA) for astrocytes and anti-Alzheimer precursor protein A4 (APP, 1:200, Chemicon International, Temecula, CA, USA). The rabbit polyclonal anti-β-amyloid antibody (ab2539) was generated against the synthetic peptide DAEFRHDSGYEVHH conjugated to KLH, corresponding to amino acids 1-14 of human β-amyloid.

After immunostaining, hemisphere sections were examined and photographed by light microscopy (Nikon Coolscope, Nikon, Düsseldorf, Germany). All sections were randomly numbered and analysed by two observers independently, who were not aware of treatments. β-amyloid plaques, APP plaque-like staining, Iba-1+ and GFAP+ cells in neocortex and hippocampus were counted. Small Aβ plaques with a dense core or larger plaques with a dense core and a large halo of diffuse amyloid were counted. Small points or spots of Aβ staining, smaller than a cellular nucleus (around 10 μm) and slightly stained diffuse amyloid without a dense core were classified as unclear deposition and were not counted. APP staining was located on cells or outside cells presenting a plaque-like expression pattern. The numbers of APP ‘plaques’ were also counted, according to the standard of Aβ plaques. Further, images of hemisphere cross-sections were captured with fixed parameters; the neocortex and hippocampus on the images were outlined and analysed using the software MetaMorph Offline 7.1 (Molecular Devices, Toronto, ON, Canada). Area percentages of specific immunoreactivity (IR) were selected by colour threshold segmentation and calculated. Results were given as arithmetic means of plaque/cell counts or area percentages of IR to interest areas on cross-sections and SEM.

**In vitro assays**

The immortalized murine macrophage cell line RAW 264.7 and microglia cell line N9 were used to determine effects of Oridonin on inflammatory reaction of macrophages and microglia in vitro. RAW 264.7 cells and N9 were seeded into 12-well cell culture plates and cultured for 24 hrs. Afterwards, cells were stimulated with lipopolysaccharide (LPS; 1 μg/ml), and incubated with or without Oridonin (1 μg/ml, dissolved in media) for 24 and 48 hrs. Thereafter, supernatants were collected for analysis of nitric oxide concentration by standard Griess assay (Sigma-Aldrich, Munich, Germany), and cells were harvested and collected. Total RNA from cultured cells was prepared, reverse transcribed into cDNA and subjected to subsequent semi-quantified PCR analysis using primers specific for mouse iNOS, IL-1β, IL-6 and β-actin. Results were calculated as levels of target mRNAs relative to those of β-actin (n = 3). In addition, cell viability was detected by MTT colorimetric assay and determined by analysis of cellular confluent and morphology, using microphotos and the software MetaMorph.

**Statistical analysis**

Differences of plaque/cell counts, area percentages, behavioural data or mRNA expression levels between treatments and controls were analysed by unpaired t-tests (Graph Pad Prism 5.0 software). For all statistical analyses, significance levels were set at *P* < 0.05.

**Results**

**Effects of oral Oridonin treatment on neuropathological changes and neuroinflammation**

Amyloid plaques were distributed throughout the whole cortex of 5 months old APP/PS1 transgenic mice, some of them were small, dense core plaques and some were larger plaques with a dense core and a large halo of diffuse amyloid. In hippocampus, obviously lower plaque density was seen.

No significant difference of Aβ deposition or of Iba-1 expression in both cortex and hippocampus could be observed between APP/PS1 mice from the control group (vehicle only) and their littermates, which received no treatment and were noted as ‘5 months’ in the figures. The oral treatment with Oridonin attenuated neuropathological changes, compared to the age- and gender-matched control mice. The Oridonin treatment reduced the plaque counts significantly in cortex (control = 144.2 ± 12.4, Oridonin = 104.8 ± 8.8, *P* < 0.05, *n* = 6) and slightly in hippocampus (control = 12.0 ± 1.9, Oridonin = 8.2 ± 1.1, *P* > 0.05, *n* = 6). It significantly decreased the Aβ IR area in both cortex and hippocampus (cortex: control = 0.47 ± 0.10%, Oridonin = 0.28 ± 0.02%, *P* < 0.05; hippocampus: control = 0.17 ± 0.01%, Oridonin = 0.08 ± 0.02%, *P* < 0.01, *n* = 6; Fig. 2). Further, in the Oridonin-treated group, Aβ plaques had a smaller size and fewer branches (Fig. 3).

APP expression in cortex and hippocampus was further investigated. The APP staining was mainly located on neurons and in/around plaques presenting a plaque-like expression pattern, as presented in the Figure 4A and B. Total areas of APP staining in cortex or hippocampus were not significantly changed after the treatment. However, the numbers of plaques covered or surrounded by APP staining were significantly reduced in cortex, but not in hippocampus (in cortex: control = 125.7 ± 8.2, Oridonin = 94.5 ± 7.0, *P* < 0.05, *n* = 6; Fig. 4C). APP staining associated with plaques in the cortex could not be quantitatively evaluated. Similar results of APP expression were obtained from the treatment with nanoemulsion injections (data not shown).

In both cortex and hippocampus, amoeboid Iba1-positive microglia were observed clustered around amyloid deposits (Fig. 3). Oridonin treatment significantly reduced the IR area of Iba-1 in cortex (control = 0.30 ± 0.05%, Oridonin = 0.18 ± 0.02%, *P* < 0.05, *n* = 6), but not in hippocampus (control = 0.14 ± 0.03%, Oridonin = 0.15 ± 0.01%, *P* > 0.05, *n* = 6; Fig. 2). There were fewer cells expressing Iba-1, major part of these Iba-1+ cells were also less clustered around plaques in cortex following Oridonin treatment, indicating reduced microglial activation (Fig. 3).

Numerous GFAP+ cells (GFAP-IR) were widely distributed throughout the hippocampus and cortex. They all showed typical morphology of astrocytes, including stellate shape and multiple branched processes. No significant changes in GFAP staining (IR area) were observed between Oridonin treatment and controls (data not shown).

1568 © 2013 The Authors, Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Effect of Oridonin-nanoemulsion injection on Aβ deposition and microglial activation

There was also no significant difference in Aβ deposition between the control group (vehicle only) and their littermates receiving no treatment, for the injection experiment at the age of 3 months. In hippocampus, from both Oridonin and control groups, Aβ deposition could be barely seen, which was in accordance with the original report that amyloid plaques appeared first in the cortex at 6 weeks of age and rather later in the hippocampus of APP/PS1 transgenic mice [17]. In the cortex of APP/PS1 mice from the Oridonin group, significantly reduced numbers of amyloid plaques were counted (control = 134.2 ± 8.8; Oridonin = 113.5 ± 5.1; P < 0.05, n = 6; Fig. 5). Area percentages of Aβ deposition (IR) were significantly reduced in the cortex as well (control = 0.33 ± 0.02%; Oridonin = 0.23 ± 0.05%; P < 0.05, n = 6; Fig. 5). Many plaques of smaller size were observed in the brains from the Oridonin-nanoeulsion group, therefore stronger reduction could be observed in area of Aβ IR.

ª 2013 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Numbers of Iba-1+ cells in cortex and hippocampus did not show a significant change following Oridonin treatment. However, Iba-1 IR was reduced by nearly the half in cortex (control = 0.31 ± 0.06%, Oridonin = 0.18 ± 0.04%, \( P < 0.05, n = 6 \)), but was only slightly decreased in the hippocampus (control = 0.11 ± 0.03%; Oridonin = 0.09 ± 0.01%; \( P > 0.05, n = 6 \); Fig. 5). In cortex from Oridonin-treated mice, major part of Iba-1+ cells were less clustered and showed smaller size and less branched morphology.

**Effect of Oridonin-nanoemulsion injection on affiliative behaviour impairment (nest construction assay)**

To assess the influence of Oridonin-nanoemulsion injection on affiliative behaviour, we analysed nest construction in naive and APP/PS1 mice. Before treatment, ability of nest construction was compared between APP/PS1 mice and naive mice, and an impaired nesting ability...
**Fig. 4** Therapeutic effect of Oridonin on APP expression. APP/PS1 mice at 5 months of age received Oridonin or vehicle by gavage for 10 days. Brains of these mice were analysed for APP expression by immunohistochemistry. (A and B) The APP staining is mainly located on neurons and in/around plaques presenting a plaque-like expression pattern, as presented in the figure. Representative microimages A and B show the changes in plaque-associated APP expression following Oridonin treatment. (C) Arithmetic means of APP plaque numbers from treatment and control groups are represented in the bar graphs. The numbers of plaques covered or surrounded by APP staining are significantly reduced in cortex. Differences of APP plaque counts between treatment and control were analysed by unpaired t-test (Graph Pad Prism 5.0 software). For all statistical analyses, significance levels were set at $P < 0.05$.

**Fig. 5** Oridonin-nanoemulsion (injection) reduced β-amyloid (Aβ) deposition and microglial activation mainly in cortex. APP/PS1 mice at 3 months of age received daily i.p. injection of Oridonin-nanoemulsion or vehicle (Lipofundin) for 10 days. Arithmetic means of IR area percentages or plaque numbers from different groups are represented in the bar graphs. Differences of plaque/cell numbers or area percentages between treatment and control were analysed by unpaired t-test (Graph Pad Prism 5.0 software). For all statistical analyses, significance levels were set at $P < 0.05$. (A and B) In the cortex of APP/PS1 mice following Oridonin-nanoemulsion injection, numbers of amyloid plaques were significantly reduced, as well as area percentages of Aβ deposition (positive pixels), compared with the control group. (C) In cortex, Iba-1 IR was reduced by nearly half in the Oridonin treatment group compared with the controls. (D) However, only slightly decreased Iba-1 IR was observed in hippocampus.
was observed for transgenic mice (naive = 2.9 ± 0.2, APP/PS1 = 1.5 ± 0.2, P < 0.05, n = 6, Fig. 6A). Right at the beginning of treatment, namely at Day 1, no significant difference between Oridonin-treated and control groups was observed (control = 1.9 ± 0.2, Oridonin = 1.8 ± 0.2, P > 0.5, n = 6, Fig. 5B). However, a significant difference between treatment and control groups could be observed at Day 11 (control = 1.4 ± 0.3, Oridonin = 2.1 ± 0.1, P < 0.05, n = 6, Fig. 5C). After the 10-days treatment of Oridonin, relatively immediate chewing and tearing behaviour towards the paper towels were observed; paper towels were torn into pieces and grouped into a corner of the cage. In contrast, APP/PS1 mice from the control group investigated and slightly chewed but did not really destruct the paper towels; paper towels were found all over in the cage, not grouped.

Oral Oridonin treatment improved impaired ability of nest construction of these transgenic mice, but not statistically significantly (data not shown).

**Effect of Oridonin-nanoemulsion injection on social interaction**

During the social interaction test, no overt differences were observed between any of the transgenic mice. The interactive behaviour of APP/PS1 mice was clearly distinct from naive and Oridonin-treated transgenic mice. Resident APP/PS1 mice showed a significantly lower frequency of interactive behaviour compared to that of naive mice (naive = 33.3 ± 3.5, APP/PS1 = 17.0 ± 3.1, P < 0.05, n = 6) and higher frequency of independent behaviour (naive = 90.7 ± 6.6, APP/PS1 = 128.0 ± 13.0, P < 0.05, n = 6) in the presence of the intruder mouse (Fig. 6E and F). Following the 10-days treatment, Oridonin-nanoemulsion restored this impairment comparable to control levels, namely increased the frequency of interactive behavioural events significantly (control = 7.7 ± 0.8; Oridonin = 15.7 ± 2.2; P < 0.05, n = 6) and decreased the frequency of independent behaviours slightly (control = 121.0 ± 9.2; Oridonin = 104.5 ± 5.4; P > 0.05, n = 6, Fig. 6G and H).

**Oridonin attenuated inflammatory activation of macrophages and microglia cell lines in vitro**

In addition, effects of Oridonin on inflammatory activation of macrophage and microglia in vitro using murine macrophage cell line RAW 264.7 and murine microglia cell line N9 were studied. Inflammatory macrophage activation was induced by LPS (1 μg/ml); with or without Oridonin treatment for 24 and 48 hrs. Following LPS induction
significantly increased nitric oxide production and mRNA expression of iNOS, IL-1β and IL-6 indicated an inflammatory activation. Oridonin significantly reduced the nitric oxide concentration and attenuated mRNA expression of iNOS, IL-1β and IL-6, suggesting an effective anti-inflammatory activity of Oridonin for both macrophage and microglia cell lines. Oridonin had very similar effects for N9 and RAW cell cultures, results from N9 cell culture are shown in the Figure 7. In addition, cell viability during treatments was proven by MTT assay and morphology analysis (data not shown).

Discussion

In this study, we describe therapeutically beneficial effects of Oridonin in a rodent model of cerebral amyloidosis. An oral treatment with Oridonin suspension significantly attenuated Aβ deposition, plaque-associated APP expression and microglial activation in both cortex and hippocampus of APP/PS1 mice at 5 months of age. Further, treatment of i.p. injection with Oridonin-nanoemulsion effectively ameliorated neuropathological changes. Interestingly, it also restored impaired nesting behaviour and social interaction.

Terpenoids are promising for treatment of neurodegenerative disorders, especially of AD [6]. Furthermore, several potent diterpenoids, such as diterpenoids from the Croton tonkinensis [7], ‘serofendic acid’ derived from foetal calf serum [8] and diterpenoids isolated from Salvia miltiorrhiza [9], are neuroprotective, promoting the survival of neurons or have acetylcholinesterase-inhibitory effects. Oridonin possesses anti-bacterial, anti-tumour and anti-inflammatory properties. Several recent studies showed that Oridonin suppressed the expression of iNOS and COX-2 through inhibition of NF-κB DNA binding [22, 23]; inhibited production of various proinflammatory cytokines, induced apoptosis of immune cells. It as well restored impaired
regulatory T cells and Th1/Th2 balance [24]. Moreover, Oridonin has been reported to have anti-neuroinflammatory and neuroregulatory effects through modulation of multiple functions of microglia, which have been implicated as culprits in many neurological disorders [15]. An important role of neuroinflammation involved in AD pathology has been reported in animal models and human [5]. Attenuated neuroinflammation has been shown to contribute to reduced hallmark features of AD pathology, including Aβ-plaque accumulation [25], and therapeutic strategies controlling the activation of microglia and the excessive production of proinflammatory factors may control neurodegeneration in dementia [26]. Modulation of nitric oxide levels has been reported in glial cells activated during the neuroinflammatory response. Cytokines such as IL-1β and IL-6 are directly involved in the development of neuroinflammation and neurodegeneration. Oridonin effectively attenuated inflammatory reaction and reduced production of nitric oxide and pro-inflammatory cytokines/molecules in our macrophage and microglia cell cultures. The levels of these cytokines/molecules were reported to correlate with amyloid load in a similar transgenic mouse model of AD [27]. Further, Oridonin significantly attenuated the microglial activation in brains of transgenic mice, suggesting an inhibitory effect of Oridonin on neuroinflammation, which may contribute to the ameliorated pathology and improved behaviour.

As a potent inhibitor of NF-κB [23], Oridonin was suggested to be of therapeutic importance for the treatment of AD pathology, not only by blocking inflammatory processes but also by directly inhibiting the production of Aβ peptides [28]. Reduced Aβ deposition and decreased plaque-related APP expression observed in our study might therefore directly attribute to NF-κB inhibition and its effect on Aβ peptides production.

Deficits in cognitive and non-mnemonic behaviours are debilitating features of most neurodegenerative diseases of the central nervous system, including AD. Toxic Aβ peptides, especially APP, inflammatory reaction and inflammation markers/molecules are all reported to be directly associated with deficits in cognitive function and behaviour [29]. Alzheimer’s disease mouse models are valuable for modelling not only cognitive impairment but also disturbances in non-mnemonic behaviours [30].

Nesting behaviour is an affiliative, social behaviour and important for the survival of animals. Impaired nesting behaviour has been observed in a similar AD rodent model, Tg2576, overexpressing APP [18]. In the APP/PS1 model, we observed similar impairment of nesting behaviour compared with the naive control. The impaired nest construction behaviour was significantly restored by Oridonin-nanoemulsion treatment.

Alzheimer’s disease is also characterized by deficits in social communication and social memory. With a comparable AD model of APP-swe/PS1 mice, impairment in social interaction has been reported: while wild-type mice were more willing to explore the stimulus mouse than an empty cage, APPswe/PS1 mice were not [31]. A more recent study reported very early (3 months) occurrence of these deficits in comparable transgenic mice and suggested that social deficits precede other neuropsychiatric and cognitive AD-like symptoms and can be employed as early markers of AD pathology in transgenic mouse models [32]. In our present study, similar deficits in social interaction of transgenic mice were observed, compared to naive littermates. Treatment with Oridonin-nanoemulsion then significantly ameliorated this impairment. Considering the relatively short term of the treatment, reduced Aβ deposition, decreased APP expression, especially plaque-associated APP density and attenuated neuroinflammatory reaction may contribute to the improved nesting behaviour and social interaction.

Recently, many experimental treatments with anti-inflammatory agents were tested in animal models of AD as well, such as: CHF5074, a non-steroidal anti-inflammatory drug [33]; aspirin-triggered LXA4 [34]; telmisartan [35]; cyclooxygenase-1 [36]; minocycline [37] and several cannabinoids [5]. They inhibited or modulated microglial activation, attenuated neuroinflammatory reaction, reduced AD-like pathology, some of them also improved cognitive deficits in transgenic mouse models of AD, similar as Oridonin’s effect observed in our present study. All these together suggest anti-inflammatory agents as a promising therapeutic option for AD.

However, it is possible that additional or other mechanisms than anti-inflammation contribute to effects of Oridonin, such as direct reduction of Aβ peptides production through NF-κB inhibition. Furthermore, Oridonin is not a general immunosuppressant, it not only inhibits overproduction of immune cells and cytokines [13] but also contributes to switch of inflammatory immune cells to regulatory cells, to maintain immune homeostasis [24]. Rabdosia rubescens and its aqueous extract including Oridonin have been applied for centuries and have shown good tolerance and safety, also in elderly patients.

Because of poor water solubility and short biological half-life of Oridonin, studies were focusing on nanostructured carriers which can provide better bioavailability, prolonged retention time in blood, improved entrapment efficiency and controlled drug release [12, 38]. More importantly, nanoemulsions also serve as a safe and effective delivery vehicle across oral and CNS barriers [39]. All of these may contribute to an increase in therapeutic effects, which is in accordance with our results, especially on behavioural improvement.

Taken together, treatments with Oridonin, suspended in cellulose or loaded by nanoemulsion, by gavage or per injection, effectively ameliorated neuroinflammatory reaction and cerebral amyloidosis in our transgenic mouse model. Oridonin-nanoemulsion injection further restored impaired affiliative and social interactive behaviours. These behavioural and pathological effects of Oridonin may be because of multiple mechanisms/factors including reduced inflammatory activation of glial cells and immune cells, decreased Aβ deposition and APP expression directly or indirectly, as well as possible neuroregulatory/protective effects through modulated microglial function and reduced local production of proinflammatory factors. All of these results suggest that Oridonin may be considered a promising therapeutic option of human AD or other neurodegenerative disorders.

Acknowledgements

The authors would like to thank Prof. M. Jucker for providing male transgenic APP/PS1-21 mice, thank Ms. C. Zug and Mr. C. Li for technical
support and assistance. We acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of Tuebingen University.

Conflicts of interest

The authors confirm that there are no conflicts of interest.

References

1. Seikoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002; 298: 789–91.
2. Herrmann N, Chau SA, Kircknani I, et al. Current and emerging drug treatment options for Alzheimer’s disease: a systematic review. Drugs. 2011; 71: 2031–65.
3. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000; 21: 383–421.
4. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease—a double-edged sword. Neuron. 2002; 35: 419–32.
5. Martin-Moreno AN, Brera B, Spuch C, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation. 2012; 9: 8.
6. Yoo KY, Park SY. Terpenoids as potential anti-Alzheimer’s disease therapeutics. Molecules. 2012; 17: 3524–38.
7. Dao TT, Le TV, Nguyen PH, et al. SIRT1 inhibitory diterpenoids from the Vietnamese medicinal plant Croton tonkinensis. Planta Med. 2010; 76: 1011–4.
8. Kume T, Katsuki H, Akaike A. Endogenous factors regulating neuronal death induced by radical stress. Bio Pharm Bull. 2004; 27: 964–7.
9. Ren Y, Houghton PJ, Hider RC, et al. Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorrhiza. Planta Med. 2004; 70: 201–4.
10. Zhang Z, Zhang X, Xue W, et al. Effects of oridonin nanosuspension on cell proliferation and apoptosis of human prostatic carcinoma PC-3 cell line. Int J Nanomedicine. 2010; 5: 735–42.
11. Ji Z, Tang Q, Zhang J, et al. Oridonin-induced apoptosis in SW620 human colorectal adenocarcinoma cells. Oncol Lett. 2011; 2: 1303–7.
12. Jia L, Shen J, Zhang D, et al. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol. 2012; 50: 523–9.
13. Liu J, Yang F, Zhang Y, et al. Studies on the cell-immunosuppressive mechanism of Oridonin from Isodon serrata. Int Immunopharmacol. 2007; 7: 945–54.
14. Chen SS, Michael A, Butler-Manuel SA. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals. Discov Med. 2012; 13: 7–17.
15. Xu Y, Xue Y, Wang Y, et al. Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol. 2009; 9: 360–5.
16. Gengler S, Hamilton A, Holscher C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer’s disease is impaired in old but not young mice. PLoS ONE. 2010; 5: e9764.
17. Radke R, Bolmont T, Kaeser SA, et al. Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006; 7: 940–6.
18. Wesson DW, Wilson DA. Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav Brain Res. 2011; 216: 408–13.
19. Hibiits P, Pannu R, Wu TJ, et al. Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination. ASN Neuro. 2009; 1: e00013.
20. Bolivar VJ, Walters SR, Phoenix JL. Assessing autism-like behavior in mice: variations in social interactions among inbred strains. Behav Brain Res. 2007; 176: 21–6.
21. Zhang Z, Zhang ZY, Fauser U, et al. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocytic infiltration into peripheral nerves. Exp Neurol. 2008; 210: 681–90.
22. Ikezoe T, Yang Y, Bandobashi K, et al. Oridonin, a diterpenoid purified from Rabdosia rhodantha, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther. 2005; 4: 578–86.
23. Leung CH, Grill SP, Lam W, et al. Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol Pharmacol. 2006; 68: 286–97.
24. Xue Y, Xue Y, Wang Y, et al. Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol. 2009; 9: 360–5.
25. Tweedle D, Ferguson RA, Fishman K, et al. Tumor necrosis factor-alpha synthesis inhibitor 3,6′-dithiothialdioxide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease. J Neuroinflammation. 2012; 9: 106.
26. Agostino P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des. 2010; 16: 2766–78.
27. Patel NS, Paris D, Mathura V, et al. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer’s disease. J Neuroinflammation. 2005; 2: 9.
28. Paris D, Patel N, Quadros A, et al. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett. 2007; 415: 11–6.
29. Owby RL. Neuroinflammation and cognitive aging. Curr Psychiatry Rep. 2010; 12: 39–45.
30. Alexander G, Hanna A, Serna V, et al. Increased aggression in males in transgenic Tg2576 mouse model of Alzheimer’s disease. Behav Brain Res. 2011; 216: 77–83.
31. Filali M, Lalonde R, Rivest S. Anomalies in social behaviors and exploratory activities in an APPswe/PS1 mouse model of Alzheimer’s disease. Physiol Behav. 2011; 104: 880–5.
32. Pietropaolo S, Delage P, Lebrton F, et al. Early development of social deficits in APP and APP-PS1 mice. Neurobiol Aging. 2012; 33: 1002, e17–27.
33. Siviglia S, Lorenzini L, Giuliani A, et al. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci. 2013; 14: 44.
34. Medeiros R, Kitazawa M, Passos GF, et al. Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol. 2013; 182: 1780–9.
35. Shindo T, Takasaki K, Uchida K, et al. Ame liorative effects of telsirican on the inflammatory response and impaired spatial memory in a rat model of Alzheimer’s disease incorporating additional cerebrovascular disease factors. Biol Pharm Bull. 2012; 35: 2141–7.
36. Choi SH, Aid S, Caracciolo L, et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease. J Neurochem. 2013; 124: 59–68.

37. Biscaro B, Lindvall O, Tesco G, et al. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer’s disease. Neurodegener Dis. 2012; 9: 187–98.

38. Dai W, Zhang D, Duan C, et al. Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system. J Microencapsul. 2010; 27: 234–41.

39. Ganta S, Deshpande D, Korde A, et al. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol. 2010; 27: 260–73.